Esther E Freeman1, Nicole C McCann2, Aggrey Semeere3, Krishna P Reddy4, Miriam Laker-Oketta5, Helen Byakwaga5, Pamela P Pei2, Maya E Hajny Fernandez2, Samson Kiprono6, Naftali Busakhala7, Jeffery N Martin8, Toby Maurer9, Ingrid V Bassett10, Kenneth A Freedberg11, Emily P Hyle10. 1. Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address: efreeman@mgh.harvard.edu. 2. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA. 3. Infectious Diseases Institute, Kampala, Uganda; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 4. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA. 5. Infectious Diseases Institute, Kampala, Uganda. 6. Department of Internal Medicine, Moi University School of Medicine, Eldoret, Kenya. 7. Department of Internal Medicine, Moi University School of Medicine, Eldoret, Kenya; Department of Pharmacology and Toxicology, Moi University School of Medicine, Eldoret, Kenya. 8. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 9. Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA. 10. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA. 11. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA; Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA.
Abstract
BACKGROUND: The most effective treatment for advanced AIDS-associated Kaposi sarcoma is paclitaxel or pegylated liposomal doxorubicin (PLD); neither is routinely used in sub-Saharan Africa due to limited availability and high cost. We examined the clinical impact, costs, and cost-effectiveness of paclitaxel or PLD in Kenya, compared with etoposide or bleomycin-vincristine. METHODS: In this study, we use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International Model to project clinical outcomes and costs among people living with HIV and advanced Kaposi sarcoma on antiretroviral therapy. We compared four different treatment strategies: etoposide, bleomycin-vincristine, paclitaxel, or PLD. We derived cohort characteristics and costs from the Kenyan Academic Model for Providing Access to Healthcare network, and adverse events, efficacy, and mortality from clinical trials. We projected model outcomes over a lifetime and included life expectancy, per-person lifetime costs, and incremental cost-effectiveness ratios (ICERs). We conducted budget impact analysis for 5-year total costs and did deterministic and probabilistic sensitivity analyses to evaluate the effect of uncertainty in input parameters. FINDINGS: We found that paclitaxel would be more effective than bleomycin-vincristine and would increase life expectancy by 4·2 years per person. PLD would further increase life expectancy by 0·6 years per person. Paclitaxel would be the most cost-effective strategy (ICER US$380 per year-of-life-saved compared with bleomycin-vincristine) and would remain cost-effective across a range of scenarios. PLD would be cost-effective compared with paclitaxel if its price were reduced to $100 per cycle (base case $180 per cycle). Implementing paclitaxel instead of bleomycin-vincristine would save approximately 6400 life-years and would increase the overall 5-year Kenyan health-care costs by $3·7 million; increased costs would be primarily related to ongoing HIV care given improved survival. INTERPRETATION: Paclitaxel would substantially increase life expectancy and be cost-effective compared with bleomycin-vincristine for advanced AIDS-associated Kaposi sarcoma in Kenya and should be the standard of care. PLD would further improve survival and be cost-effective with a 44% price reduction. FUNDING: US National Institutes of Health and Massachusetts General Hospital. TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.
BACKGROUND: The most effective treatment for advanced AIDS-associated Kaposi sarcoma is paclitaxel or pegylated liposomal doxorubicin (PLD); neither is routinely used in sub-Saharan Africa due to limited availability and high cost. We examined the clinical impact, costs, and cost-effectiveness of paclitaxel or PLD in Kenya, compared with etoposide or bleomycin-vincristine. METHODS: In this study, we use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International Model to project clinical outcomes and costs among people living with HIV and advanced Kaposi sarcoma on antiretroviral therapy. We compared four different treatment strategies: etoposide, bleomycin-vincristine, paclitaxel, or PLD. We derived cohort characteristics and costs from the Kenyan Academic Model for Providing Access to Healthcare network, and adverse events, efficacy, and mortality from clinical trials. We projected model outcomes over a lifetime and included life expectancy, per-person lifetime costs, and incremental cost-effectiveness ratios (ICERs). We conducted budget impact analysis for 5-year total costs and did deterministic and probabilistic sensitivity analyses to evaluate the effect of uncertainty in input parameters. FINDINGS: We found that paclitaxel would be more effective than bleomycin-vincristine and would increase life expectancy by 4·2 years per person. PLD would further increase life expectancy by 0·6 years per person. Paclitaxel would be the most cost-effective strategy (ICER US$380 per year-of-life-saved compared with bleomycin-vincristine) and would remain cost-effective across a range of scenarios. PLD would be cost-effective compared with paclitaxel if its price were reduced to $100 per cycle (base case $180 per cycle). Implementing paclitaxel instead of bleomycin-vincristine would save approximately 6400 life-years and would increase the overall 5-year Kenyan health-care costs by $3·7 million; increased costs would be primarily related to ongoing HIV care given improved survival. INTERPRETATION: Paclitaxel would substantially increase life expectancy and be cost-effective compared with bleomycin-vincristine for advanced AIDS-associated Kaposi sarcoma in Kenya and should be the standard of care. PLD would further improve survival and be cost-effective with a 44% price reduction. FUNDING: US National Institutes of Health and Massachusetts General Hospital. TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.
Authors: Celeste Lebbe; Claus Garbe; Alexander J Stratigos; Catherine Harwood; Ketty Peris; Veronique Del Marmol; Josep Malvehy; Iris Zalaudek; Christoph Hoeller; Reinhard Dummer; Ana Maria Forsea; Lidija Kandolf-Sekulovic; Judith Olah; Petr Arenberger; Matilda Bylaite-Bucinskiene; Ricardo Vieira; Mark Middleton; Antonin Levy; Alexander M Eggermont; Maxime Battistella; Jean Philippe Spano; Jean Jacques Grob; Cecile Pages Journal: Eur J Cancer Date: 2019-05-13 Impact factor: 9.162
Authors: S Stewart; H Jablonowski; F D Goebel; K Arasteh; M Spittle; A Rios; D Aboulafia; J Galleshaw; B J Dezube Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: Erin Reid; Gita Suneja; Richard F Ambinder; Kevin Ard; Robert Baiocchi; Stefan K Barta; Evie Carchman; Adam Cohen; Oxana V Crysler; Neel Gupta; Chelsea Gustafson; Allison Hall; Kimberly L Johung; Ann Klopp; Ann S LaCasce; Chi Lin; Amitkumar Mehta; Manoj P Menon; David Morgan; Nitya Nathwani; Ariela Noy; Lee Ratner; Stacey Rizza; Michelle A Rudek; Julian Sanchez; Jeff Taylor; Benjamin Tomlinson; Chia-Ching J Wang; Sai Yendamuri; Mary A Dwyer; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2019-02 Impact factor: 11.908
Authors: Christa Slaught; Victoria Williams; Surbhi Grover; Elizabeth Bigger; Mukendi Kayembe; Sebathu Chiyapo; Nicholas J Jackson; Scott Dryden-Peterson; Carrie L Kovarik; Karolyn A Wanat Journal: Int J Dermatol Date: 2018-11-21 Impact factor: 3.204
Authors: Eliane Rohner; Margaret Kasaro; Susan Citonje Msadabwe-Chikuni; Kathryn Stinson; Zainab Mohamed; Hannock Tweya; Matthias Egger; Julia Bohlius Journal: Pan Afr Med J Date: 2017-11-24
Authors: Krishna P Reddy; Ankur Gupta-Wright; Katherine L Fielding; Sydney Costantini; Amy Zheng; Elizabeth L Corbett; Liyang Yu; Joep J van Oosterhout; Stephen C Resch; Douglas P Wilson; C Robert Horsburgh; Robin Wood; Melanie Alufandika-Moyo; Jurgens A Peters; Kenneth A Freedberg; Stephen D Lawn; Rochelle P Walensky Journal: Lancet Glob Health Date: 2019-02 Impact factor: 26.763